Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction

Atrial fibrillation (AFib) is frequently associated with heart failure. Guidelines for AFib management have been recently updated and include an algorithm for acute heart rate control based on left ventricular ejection fraction and haemodynamics. Landiolol is an injectable ultra-short beta-blocker w...

Descripción completa

Detalles Bibliográficos
Autores principales: von Haehling, Stephan, Bělohlávek, Jan, Er, Fikret, Gassanov, Natig, Guarracino, Fabio, Bouvet, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909772/
https://www.ncbi.nlm.nih.gov/pubmed/30188957
http://dx.doi.org/10.1093/eurheartj/sux035
_version_ 1783315955299909632
author von Haehling, Stephan
Bělohlávek, Jan
Er, Fikret
Gassanov, Natig
Guarracino, Fabio
Bouvet, Olivier
author_facet von Haehling, Stephan
Bělohlávek, Jan
Er, Fikret
Gassanov, Natig
Guarracino, Fabio
Bouvet, Olivier
author_sort von Haehling, Stephan
collection PubMed
description Atrial fibrillation (AFib) is frequently associated with heart failure. Guidelines for AFib management have been recently updated and include an algorithm for acute heart rate control based on left ventricular ejection fraction and haemodynamics. Landiolol is an injectable ultra-short beta-blocker with very high beta-1 selectivity, listed in Japanese Guidelines for AFib management as potential option for rate control of patient with heart failure. Landiolol is now available in Europe with indication of controlling heart rate in AFib and supraventricular tachycardia. This review discusses existing clinical data in Japan and perspectives of landiolol use for acute rate control of AFib patients with cardiac dysfunction.
format Online
Article
Text
id pubmed-5909772
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-59097722018-04-24 Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction von Haehling, Stephan Bělohlávek, Jan Er, Fikret Gassanov, Natig Guarracino, Fabio Bouvet, Olivier Eur Heart J Suppl Articles Atrial fibrillation (AFib) is frequently associated with heart failure. Guidelines for AFib management have been recently updated and include an algorithm for acute heart rate control based on left ventricular ejection fraction and haemodynamics. Landiolol is an injectable ultra-short beta-blocker with very high beta-1 selectivity, listed in Japanese Guidelines for AFib management as potential option for rate control of patient with heart failure. Landiolol is now available in Europe with indication of controlling heart rate in AFib and supraventricular tachycardia. This review discusses existing clinical data in Japan and perspectives of landiolol use for acute rate control of AFib patients with cardiac dysfunction. Oxford University Press 2018-01 2018-01-08 /pmc/articles/PMC5909772/ /pubmed/30188957 http://dx.doi.org/10.1093/eurheartj/sux035 Text en Published on behalf of the European Society of Cardiology. © The Author 2018. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Articles
von Haehling, Stephan
Bělohlávek, Jan
Er, Fikret
Gassanov, Natig
Guarracino, Fabio
Bouvet, Olivier
Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction
title Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction
title_full Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction
title_fullStr Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction
title_full_unstemmed Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction
title_short Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction
title_sort landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909772/
https://www.ncbi.nlm.nih.gov/pubmed/30188957
http://dx.doi.org/10.1093/eurheartj/sux035
work_keys_str_mv AT vonhaehlingstephan landiololforratecontrolmanagementofatrialfibrillationinpatientswithcardiacdysfunction
AT belohlavekjan landiololforratecontrolmanagementofatrialfibrillationinpatientswithcardiacdysfunction
AT erfikret landiololforratecontrolmanagementofatrialfibrillationinpatientswithcardiacdysfunction
AT gassanovnatig landiololforratecontrolmanagementofatrialfibrillationinpatientswithcardiacdysfunction
AT guarracinofabio landiololforratecontrolmanagementofatrialfibrillationinpatientswithcardiacdysfunction
AT bouvetolivier landiololforratecontrolmanagementofatrialfibrillationinpatientswithcardiacdysfunction

Ejemplares similares